Stable excess mortality in a multiple sclerosis cohort diagnosed 1970-2010.

ABSTRACT:

Background and purpose

Multiple sclerosis (MS) is associated with excess mortality. The use of disease-modifying treatments (DMTs) has recently been associated with survival benefits.

Methods

A regional MS database was linked with national registries. People with MS (pwMS) diagnosed in 1971-2010 were included and followed up until the end of the year 2019. Five matched controls were acquired for every person with MS. DMTs included in the analyses were interferon and glatiramer acetate.

Results

Median follow-up time of the 1795 pwMS was 20.0 years (range 0.1-48.7 years). Survival did not differ between decades of diagnosis (p = 0.20). Amongst pwMS, male sex (adjusted hazard ratio [aHR] 1.70; 95% confidence interval [CI] 1.41-2.06), higher age at diagnosis (aHR 1.83; 95

SUBMITTER: Sumelahti ML 

PROVIDER: S-EPMC11554857 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature